Plain-English translation of NCT07755397 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human trial testing a new medication called as a treatment for three specific types of advanced cancer: lung cancer with an EGFR mutation, a type of brain tumor called IDH-mutated glioma, and adenoid cystic carcinoma (a salivary gland cancer). Researchers will start with small doses and gradually increase them to find the safest and most effective dose of this medication. The goal is to understand how the medication works in your body and whether it can help slow or shrink these cancers.
These three cancers are difficult to treat, especially when they've stopped responding to existing medications or have spread to the brain. This new treatment is designed to work on specific mutations found in these cancers, and researchers hope it may offer a new option for patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once daily in cycles of 21 days. The trial starts with a low dose, and the dose increases gradually as the study progresses—the research team closely watches for any side effects to find the safest effective dose. You will have regular visits for blood work, scans to measure your tumor, and possibly biopsies (small tissue samples) to help researchers understand how the medication is working. Your participation may last several months or longer depending on how well you respond and tolerate the treatment.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
India